NCT04982224
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04982224
Title Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Irvine School of Medicine - Suite 400, Room 407 Orange California 92868 United States Details
University of Colorado Hospital Anshutz Outpatient Pavillion Denver Colorado 80045 United States Details
Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building Baltimore Maryland 21231 United States Details
Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building Baltimore Maryland 21231 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Henry Ford Hospital, Henry Ford Cancer Institute Detroit Michigan 48202 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of Pittsburgh Medical Center - Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
MUSC Hollings Cancer Center Charleston South Carolina 29425 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Next Virginia Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field